Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 4/20 | 0.39 |
| ▸ | NPC1 | O15118 | 3/20 | 0.39 |
| ▸ | CASP3 | P42574 | 1/20 | 0.39 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.39 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.39 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.39 |
| ▸ | ATM | Q13315 | 1/20 | 0.38 |
| ▸ | RBBP9 | O75884 | 1/20 | 0.38 |
| ▸ | PKM | P14618 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | MIF | P14174 | 2/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2303013 | 0.85 | RAB9A (0.41) | RAB9ANPC1CASP3SENP8SENP7 | |
| SCHEMBL791232 | 0.72 | BRD4 (0.46) | ALDH1A1POLB | |
| SCHEMBL3154349 | 0.71 | — | — | |
| SCHEMBL4941703 | 0.71 | ESR2 (0.37) | LMNAALDH1A1 | |
| SCHEMBL8970166 | 0.70 | RBBP9 (0.41) | RAB9ANPC1CASP3SENP8SENP7 | |
| Ethylene SCHEMBL11701928 | 0.69 | BRD4 (0.43) | ALDH1A1POLB | |
| SCHEMBL3626745 | 0.69 | ESR2 (0.35) | LMNAALDH1A1 | |
| SCHEMBL1148096 | 0.69 | SMN1; SMN2 (0.40) | RAB9ANPC1CASP3SENP8SENP7 | |
| SCHEMBL15163817 | 0.69 | BRD4 (0.41) | RAB9ANPC1CASP3SENP8SENP7 | |
| SCHEMBL21510460 | 0.69 | HTT (0.33) | KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1773796-B1 | OXOPIPERIDINE DERIVATIVES, PREPARATION AND THERAPEUTIC USE THEREOF | SANOFI AVENTIS (FR) | 2010-03-03 | — | — | EP | disclosed |
| US-20070149562-A1 | OXOPIPERIDINE DERIVATIVES, PREPARATION AND THERAPEUTIC USE THEREOF | SANOFI-AVENTIS (FR) | 2007-06-28 | — | — | US | disclosed |
| EP-1773796-A2 | OXOPIPERIDINE DERIVATIVES, PREPARATION AND THERAPEUTIC USE THEREOF | Sanofi-Aventis (FR) | 2007-04-18 | — | — | EP | disclosed |
| WO-2006021655-A2 | OXOPIPERIDINE DERIVATIVES, PREPARATION AND THERAPEUTIC USE THEREOF | SANOFI-AVENTIS (FR) | 2006-03-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070149562-A1 | OXOPIPERIDINE DERIVATIVES, PREPARATION AND THERAPEUTIC USE THEREOF | MC5R, MC4R, OPRD1 | RAB9A 2337/4885NPC1 3469/4885CASP3 2760/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.